A study published in Arthritis Research & Therapy found that patients with rheumatoid arthritis (RA) treated with upadacitinib over 5 years showed greater reductions in disease activity compared to methotrexate. The study also found that upadacitinib had a more favorable risk-benefit profile than methotrexate. The long-term extension of the phase 3 SELECT-EARLY trial included 775 participants who completed the original trial, with upadacitinib showing better responses in terms of disease activity and remission rates compared to methotrexate. Despite some safety concerns, the study suggests that upadacitinib may be an effective treatment option for patients with RA.
Source link
Long-term upadacitinib superior to methotrexate for rheumatoid arthritis
